103516-75-2C1CCC(C(CC2CCCCN2)C2CCCCC2)CC1.O=C(O)/C=C\C(=O)OJDZOTSLZMQDFLG-BTJKTKAUSA-NPERHEXILINE MALEATE is a small molecule drug with a maximum clinical trial phase of IV that was first approved in 1974. It was withdrawn in at least one region.
化学的特性White Solid
安全情報は参考情報です。供給元の安全データシート(SDS)、適用法令、専門家による評価に代わるものではありません。
Drug-Induced Liver Injury Severity and Toxicity (DILIst)
perhexiline maleate
DILI Positive
DOI:10.1016/j.drudis.2019.09.022
説明Perhexiline is a carnitine palmitoyltransferase 1 (CPT1) and CPT2 inhibitor that was originally developed as an anti-anginal drug in the 1970s. It inhibits rat heart and liver CPT1 (IC50 = 77 and 148 μM, respectively) and rat heart CPT2 (IC50 = 79 μM). Inhibition of CPT reduces uptake of long-chain fatty acids into the mitochondria, thereby shifting cellular metabolism from β-oxidation to glycolysis. Perhexilin inhibits mTORC1 signaling at 10 μM and induces autophagy ~7-fold at a concentration of 10 μM in MCF-7 cells.
使用PERHEXILINE MALEATE SALT is a Vasodilator, used in treatments for angina.
一般的な説明Perhexiline maleate regulatescoronary vasodilatation and blocks exercise-induced tachycardia. It is used to treat angina pectoris and variant angina. Perhexiline maleate functions as a cardiac metabolic agent. It is associated with peripheral neuropathy, high intracranial pressure withpapilledemaand proximal myopathy.
現在のフィルター条件では反応記録がありません。
読み込み中…
103516-75-2、103516-76-3、6724-53-4DTXSID1021114CHEMBL1334033CHEBI:232991